Nivalis Therapeutics, Inc. clinical trials
Acquired by Vertex Pharmaceuticals Incorporated, May 18, 2024 · source ↗
The registry lists 11 studies whose lead sponsor is Nivalis Therapeutics, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 31, 2017.
Before and after it joined Vertex Pharmaceuticals Incorporated
- First submitted before Nivalis Therapeutics, Inc. became part of Vertex Pharmaceuticals Incorporated
- 11
- First submitted after Nivalis Therapeutics, Inc. became part of Vertex Pharmaceuticals Incorporated
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Nivalis Therapeutics, Inc.11 studies
Something wrong with this grouping? Tell us on the Vertex Pharmaceuticals Incorporated page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All Vertex Pharmaceuticals Incorporated studies →
- MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)CompletedNCT02934139Phase 1
Sponsor listed in the registry: Nivalis Therapeutics, Inc. · First submitted before Nivalis Therapeutics, Inc. became part of Vertex Pharmaceuticals Incorporated
- Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR MutationCompletedNCT02589236Phase 2
Sponsor listed in the registry: Nivalis Therapeutics, Inc. · First submitted before Nivalis Therapeutics, Inc. became part of Vertex Pharmaceuticals Incorporated
- MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy SubjectsCompletedNCT02013388Phase 1
Sponsor listed in the registry: Nivalis Therapeutics, Inc. · First submitted before Nivalis Therapeutics, Inc. became part of Vertex Pharmaceuticals Incorporated
- Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With IvacaftorStatus unknownNCT02724527Phase 2
Sponsor listed in the registry: Nivalis Therapeutics, Inc. · First submitted before Nivalis Therapeutics, Inc. became part of Vertex Pharmaceuticals Incorporated
- A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult SubjectsCompletedNCT02500667Phase 1
Sponsor listed in the registry: Nivalis Therapeutics, Inc. · First submitted before Nivalis Therapeutics, Inc. became part of Vertex Pharmaceuticals Incorporated
- Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR MutationCompletedNCT02275936Phase 1
Sponsor listed in the registry: Nivalis Therapeutics, Inc. · First submitted before Nivalis Therapeutics, Inc. became part of Vertex Pharmaceuticals Incorporated
- PK Study of N91115 in Cystic Fibrosis PatientsCompletedNCT02227888Phase 1
Sponsor listed in the registry: Nivalis Therapeutics, Inc. · First submitted before Nivalis Therapeutics, Inc. became part of Vertex Pharmaceuticals Incorporated
- A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy SubjectsCompletedNCT01339897Phase 1
Sponsor listed in the registry: Nivalis Therapeutics, Inc. · First submitted before Nivalis Therapeutics, Inc. became part of Vertex Pharmaceuticals Incorporated
- Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR MutationCompletedNCT01746784Phase 1
Sponsor listed in the registry: Nivalis Therapeutics, Inc. · First submitted before Nivalis Therapeutics, Inc. became part of Vertex Pharmaceuticals Incorporated
- Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild AsthmaCompletedNCT01316315Phase 1/2
Sponsor listed in the registry: Nivalis Therapeutics, Inc. · First submitted before Nivalis Therapeutics, Inc. became part of Vertex Pharmaceuticals Incorporated
- Safety and Tolerability Study of N6022 in Healthy SubjectsCompletedNCT01147406Phase 1
Sponsor listed in the registry: Nivalis Therapeutics, Inc. · First submitted before Nivalis Therapeutics, Inc. became part of Vertex Pharmaceuticals Incorporated